SPECIFIC ANTIBODIES TO ALPHA-ENOLASE AND METHOD OF USING IN IMMUNE DISEASES

FIELD: biotechnologies.SUBSTANCE: invention relates to the biotechnology. Described is a method of treating an inflammatory disease, comprising administering to an individual in need thereof an ENO1 antibody, where the antibody specifically binds to the epitope on ENO1 and inhibits ENO1 activity as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CHYA Vej-Tso, SHI Nen-Yao, CHEN Li-Ttszun, TSEN Shi-Chi, TSAJ Shi-Chun, LYU Ko-Tszyunn, CHAN Minl, YUAN Ta-Tun, CHEN Shuj-Tszo, VAN Khsin-Yun
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator CHYA Vej-Tso
SHI Nen-Yao
CHEN Li-Ttszun
TSEN Shi-Chi
TSAJ Shi-Chun
LYU Ko-Tszyunn
CHAN Minl
YUAN Ta-Tun
CHEN Shuj-Tszo
VAN Khsin-Yun
description FIELD: biotechnologies.SUBSTANCE: invention relates to the biotechnology. Described is a method of treating an inflammatory disease, comprising administering to an individual in need thereof an ENO1 antibody, where the antibody specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKS(SEQ ID NO:39) ENO1 human, where the inflammatory disease is selected from a group consisting of multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, atherosclerosis and their combination. Also described is a method of treating an immune disorder, comprising administering to an individual in need thereof an ENO1 antibody, where the antibody binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where the epitope is located in a region consisting of sequence 296FDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKS336 (SEQ ID NO:39) human ENO1, wherein the immune disorder is selected from a group consisting of chronic obstructive pulmonary disease (COPD), type 1 diabetes, osteoporosis, atherosclerosis and combinations thereof. Disclosed is a pharmaceutical composition for treating an inflammatory disease comprising an effective amount of an antibody or fragment thereof scFv, Fab or F (ab), which specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVG DDLTVTNPKRIAKAVNEKS(SEQ ID NO: 39) human ENO1, where the inflammatory disease is selected from a group consisting of multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, atherosclerosis and a combination thereof. Also provided is a pharmaceutical composition for treating an immune disorder comprising an effective amount of an antibody or fragment thereof scFv, Fab or F(ab), which specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVG DDLTVTNPKRIAKAVNEKS(SEQ ID NO:39) human ENO1, wherein the immune disorder is selected from a group consisting of chronic obstructive pulmonary disease (COPD), t
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_RU2707812C1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>RU2707812C1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_RU2707812C13</originalsourceid><addsrcrecordid>eNqNyjEOwjAMQNEsDAi4gy9QiZahrGniEIsmrnAyVxUKE4JK5f6iAwdg-sN_W3WVAQ05MqBjoo4toUBi0P3gdYWRey24PgsBk2cL7CALxQtQBAohRwRLgquSvdo8pudSDr_uFDhMxldlfo9lmad7eZXPeMtNe2zPdWPq0x_kCwQgLP8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>SPECIFIC ANTIBODIES TO ALPHA-ENOLASE AND METHOD OF USING IN IMMUNE DISEASES</title><source>esp@cenet</source><creator>CHYA Vej-Tso ; SHI Nen-Yao ; CHEN Li-Ttszun ; TSEN Shi-Chi ; TSAJ Shi-Chun ; LYU Ko-Tszyunn ; CHAN Minl ; YUAN Ta-Tun ; CHEN Shuj-Tszo ; VAN Khsin-Yun</creator><creatorcontrib>CHYA Vej-Tso ; SHI Nen-Yao ; CHEN Li-Ttszun ; TSEN Shi-Chi ; TSAJ Shi-Chun ; LYU Ko-Tszyunn ; CHAN Minl ; YUAN Ta-Tun ; CHEN Shuj-Tszo ; VAN Khsin-Yun</creatorcontrib><description>FIELD: biotechnologies.SUBSTANCE: invention relates to the biotechnology. Described is a method of treating an inflammatory disease, comprising administering to an individual in need thereof an ENO1 antibody, where the antibody specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKS(SEQ ID NO:39) ENO1 human, where the inflammatory disease is selected from a group consisting of multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, atherosclerosis and their combination. Also described is a method of treating an immune disorder, comprising administering to an individual in need thereof an ENO1 antibody, where the antibody binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where the epitope is located in a region consisting of sequence 296FDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKS336 (SEQ ID NO:39) human ENO1, wherein the immune disorder is selected from a group consisting of chronic obstructive pulmonary disease (COPD), type 1 diabetes, osteoporosis, atherosclerosis and combinations thereof. Disclosed is a pharmaceutical composition for treating an inflammatory disease comprising an effective amount of an antibody or fragment thereof scFv, Fab or F (ab), which specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVG DDLTVTNPKRIAKAVNEKS(SEQ ID NO: 39) human ENO1, where the inflammatory disease is selected from a group consisting of multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, atherosclerosis and a combination thereof. Also provided is a pharmaceutical composition for treating an immune disorder comprising an effective amount of an antibody or fragment thereof scFv, Fab or F(ab), which specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVG DDLTVTNPKRIAKAVNEKS(SEQ ID NO:39) human ENO1, wherein the immune disorder is selected from a group consisting of chronic obstructive pulmonary disease (COPD), type 1 diabetes, osteoporosis, atherosclerosis and combinations thereof.EFFECT: invention extends the range of products for treating inflammatory and immune disorders.11 cl, 14 dwg, 2 tbl, 2 ex</description><language>eng ; rus</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20191129&amp;DB=EPODOC&amp;CC=RU&amp;NR=2707812C1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20191129&amp;DB=EPODOC&amp;CC=RU&amp;NR=2707812C1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CHYA Vej-Tso</creatorcontrib><creatorcontrib>SHI Nen-Yao</creatorcontrib><creatorcontrib>CHEN Li-Ttszun</creatorcontrib><creatorcontrib>TSEN Shi-Chi</creatorcontrib><creatorcontrib>TSAJ Shi-Chun</creatorcontrib><creatorcontrib>LYU Ko-Tszyunn</creatorcontrib><creatorcontrib>CHAN Minl</creatorcontrib><creatorcontrib>YUAN Ta-Tun</creatorcontrib><creatorcontrib>CHEN Shuj-Tszo</creatorcontrib><creatorcontrib>VAN Khsin-Yun</creatorcontrib><title>SPECIFIC ANTIBODIES TO ALPHA-ENOLASE AND METHOD OF USING IN IMMUNE DISEASES</title><description>FIELD: biotechnologies.SUBSTANCE: invention relates to the biotechnology. Described is a method of treating an inflammatory disease, comprising administering to an individual in need thereof an ENO1 antibody, where the antibody specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKS(SEQ ID NO:39) ENO1 human, where the inflammatory disease is selected from a group consisting of multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, atherosclerosis and their combination. Also described is a method of treating an immune disorder, comprising administering to an individual in need thereof an ENO1 antibody, where the antibody binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where the epitope is located in a region consisting of sequence 296FDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKS336 (SEQ ID NO:39) human ENO1, wherein the immune disorder is selected from a group consisting of chronic obstructive pulmonary disease (COPD), type 1 diabetes, osteoporosis, atherosclerosis and combinations thereof. Disclosed is a pharmaceutical composition for treating an inflammatory disease comprising an effective amount of an antibody or fragment thereof scFv, Fab or F (ab), which specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVG DDLTVTNPKRIAKAVNEKS(SEQ ID NO: 39) human ENO1, where the inflammatory disease is selected from a group consisting of multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, atherosclerosis and a combination thereof. Also provided is a pharmaceutical composition for treating an immune disorder comprising an effective amount of an antibody or fragment thereof scFv, Fab or F(ab), which specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVG DDLTVTNPKRIAKAVNEKS(SEQ ID NO:39) human ENO1, wherein the immune disorder is selected from a group consisting of chronic obstructive pulmonary disease (COPD), type 1 diabetes, osteoporosis, atherosclerosis and combinations thereof.EFFECT: invention extends the range of products for treating inflammatory and immune disorders.11 cl, 14 dwg, 2 tbl, 2 ex</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyjEOwjAMQNEsDAi4gy9QiZahrGniEIsmrnAyVxUKE4JK5f6iAwdg-sN_W3WVAQ05MqBjoo4toUBi0P3gdYWRey24PgsBk2cL7CALxQtQBAohRwRLgquSvdo8pudSDr_uFDhMxldlfo9lmad7eZXPeMtNe2zPdWPq0x_kCwQgLP8</recordid><startdate>20191129</startdate><enddate>20191129</enddate><creator>CHYA Vej-Tso</creator><creator>SHI Nen-Yao</creator><creator>CHEN Li-Ttszun</creator><creator>TSEN Shi-Chi</creator><creator>TSAJ Shi-Chun</creator><creator>LYU Ko-Tszyunn</creator><creator>CHAN Minl</creator><creator>YUAN Ta-Tun</creator><creator>CHEN Shuj-Tszo</creator><creator>VAN Khsin-Yun</creator><scope>EVB</scope></search><sort><creationdate>20191129</creationdate><title>SPECIFIC ANTIBODIES TO ALPHA-ENOLASE AND METHOD OF USING IN IMMUNE DISEASES</title><author>CHYA Vej-Tso ; SHI Nen-Yao ; CHEN Li-Ttszun ; TSEN Shi-Chi ; TSAJ Shi-Chun ; LYU Ko-Tszyunn ; CHAN Minl ; YUAN Ta-Tun ; CHEN Shuj-Tszo ; VAN Khsin-Yun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_RU2707812C13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; rus</language><creationdate>2019</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>CHYA Vej-Tso</creatorcontrib><creatorcontrib>SHI Nen-Yao</creatorcontrib><creatorcontrib>CHEN Li-Ttszun</creatorcontrib><creatorcontrib>TSEN Shi-Chi</creatorcontrib><creatorcontrib>TSAJ Shi-Chun</creatorcontrib><creatorcontrib>LYU Ko-Tszyunn</creatorcontrib><creatorcontrib>CHAN Minl</creatorcontrib><creatorcontrib>YUAN Ta-Tun</creatorcontrib><creatorcontrib>CHEN Shuj-Tszo</creatorcontrib><creatorcontrib>VAN Khsin-Yun</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CHYA Vej-Tso</au><au>SHI Nen-Yao</au><au>CHEN Li-Ttszun</au><au>TSEN Shi-Chi</au><au>TSAJ Shi-Chun</au><au>LYU Ko-Tszyunn</au><au>CHAN Minl</au><au>YUAN Ta-Tun</au><au>CHEN Shuj-Tszo</au><au>VAN Khsin-Yun</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>SPECIFIC ANTIBODIES TO ALPHA-ENOLASE AND METHOD OF USING IN IMMUNE DISEASES</title><date>2019-11-29</date><risdate>2019</risdate><abstract>FIELD: biotechnologies.SUBSTANCE: invention relates to the biotechnology. Described is a method of treating an inflammatory disease, comprising administering to an individual in need thereof an ENO1 antibody, where the antibody specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKS(SEQ ID NO:39) ENO1 human, where the inflammatory disease is selected from a group consisting of multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, atherosclerosis and their combination. Also described is a method of treating an immune disorder, comprising administering to an individual in need thereof an ENO1 antibody, where the antibody binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where the epitope is located in a region consisting of sequence 296FDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKS336 (SEQ ID NO:39) human ENO1, wherein the immune disorder is selected from a group consisting of chronic obstructive pulmonary disease (COPD), type 1 diabetes, osteoporosis, atherosclerosis and combinations thereof. Disclosed is a pharmaceutical composition for treating an inflammatory disease comprising an effective amount of an antibody or fragment thereof scFv, Fab or F (ab), which specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVG DDLTVTNPKRIAKAVNEKS(SEQ ID NO: 39) human ENO1, where the inflammatory disease is selected from a group consisting of multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, atherosclerosis and a combination thereof. Also provided is a pharmaceutical composition for treating an immune disorder comprising an effective amount of an antibody or fragment thereof scFv, Fab or F(ab), which specifically binds to the epitope on ENO1 and inhibits ENO1 activity as a plasminogen receptor, where epitope is located in region consisting of sequenceFDQDDWGAWQKFTASAGIQVVG DDLTVTNPKRIAKAVNEKS(SEQ ID NO:39) human ENO1, wherein the immune disorder is selected from a group consisting of chronic obstructive pulmonary disease (COPD), type 1 diabetes, osteoporosis, atherosclerosis and combinations thereof.EFFECT: invention extends the range of products for treating inflammatory and immune disorders.11 cl, 14 dwg, 2 tbl, 2 ex</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; rus
recordid cdi_epo_espacenet_RU2707812C1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title SPECIFIC ANTIBODIES TO ALPHA-ENOLASE AND METHOD OF USING IN IMMUNE DISEASES
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T06%3A04%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CHYA%20Vej-Tso&rft.date=2019-11-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ERU2707812C1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true